Russia has announced significant progress on its new cancer vaccine, Enteromix, claiming 100% efficacy in preclinical trials for colorectal cancer. The mRNA-based therapeutic vaccine, developed by the Federal Medical and Biological Agency (FMBA), targets tumor-specific antigens to train the immune system against cancer cells. Officials state it reduced tumor sizes and slowed growth in animal models, with human Phase I trials expected soon.
Enteromix uses lipid nanoparticles to deliver mRNA, building on Russia's Sputnik V technology. Unlike preventive vaccines, it treats existing cancers by personalizing to patient tumors. Veronika Skvortsova, FMBA head, highlighted its safety for repeated doses. Russia plans free access nationwide if approved, potentially by mid-2026.
Experts caution that preclinical results often don't translate fully to humans, citing global mRNA cancer vaccine trials showing 40-50% response rates. Russia joins US, UK efforts amid a projected $10B market. No Phase III data yet; skeptics note hype around early claims. Optimism persists for combination with immunotherapies.
